

For Immediate Release
For Further Information Contact:
Andrew Fisher at (202) 483-7000
Email: Afisher@unither.com

**REMODULIN® LONG-TERM SURVIVAL DATA PRESENTED AT
AMERICAN HEART ASSOCIATION CONFERENCE**

Silver Spring, MD, November 20, 2002: United Therapeutics Corporation (NASDAQ: UTHR) announced today that a preliminary assessment of potential survival benefit associated with Remodulin® (treprostinil sodium) Injection therapy was presented at the American Heart Association's 75th Scientific Sessions meeting in Chicago, Illinois.

Dr. J. Simon R Gibbs, Consultant Cardiologist at the Hammersmith Hospital, London, presented a preliminary analysis of 843 pulmonary arterial hypertension patients treated with Remodulin. The analysis indicates that patients suffering with forms of pulmonary arterial hypertension, a life-threatening disease, may increase their chance of survival if treated with Remodulin. According to the National Institutes of Health patient registry, patients with the primary pulmonary hypertension form of the disease are expected to have only a 46% chance of surviving three years if untreated. However, data presented today shows that similar patients if treated with Remodulin would increase their survival rate to 69.83% at three years.

"This preliminary analysis provides supporting evidence that treatment with Remodulin confers long-term benefits for patients with pulmonary arterial hypertension," said Dr. Gibbs.

Remodulin (treprostinil sodium) Injection is indicated as a continuous subcutaneous infusion for the treatment of pulmonary arterial hypertension in patients with NYHA Class II-IV symptoms to diminish symptoms associated with exercise. In clinical trials, the most common side effects reported with Remodulin therapy included infusion site pain (85%) and infusion site reaction (83%). Other adverse events included headache (27%), diarrhea (25%), nausea (22%), rash (14%), jaw pain (13%), vasodilatation (11%), dizziness (9%), edema (9%), pruritus (8%) and hypotension (4%). Remodulin should be used only by clinicians experienced in the diagnosis and treatment of PAH.

United Therapeutics is a biotechnology company focused on combating chronic and life-threatening cardiovascular, infectious and oncological diseases with unique therapeutic products.

* * *